The therapeutic application of Amfexa (dexamfetamine sulfate) is commonly used for managing specific, pronounced symptoms associated with two core neurological conditions. The medication is relevant across therapeutic domains involving chronic deficits in attention regulation and pathological sleep-wake cycles.

---

Amfexa is commonly used as an integral part of a comprehensive treatment program for Attention-Deficit/Hyperactivity Disorder (ADHD) in pediatric, adolescent, and adult populations, and is also indicated for the symptomatic management of narcolepsy. It is applied in addressing core symptoms that interfere with daily functioning, including short attention span, marked distractibility, excessive hyperactivity, and debilitating daytime sleepiness.

The medication supports the ability to maintain focus, helps moderate impulsive behavior, and assists with promoting sustained wakefulness. This support is relevant in clinical settings where symptoms create noticeable physiological strain and may affect functional stability.

“The supportive use of this medication helps provide relief and assists patients in coping more steadily with symptom fluctuations in their day-to-day lives.”

---

Quick Fact: Relief for Attention and Wakefulness Deficits

This medication is often used when supportive symptom management is appropriate for conditions characterized by deficits in executive function and excessive daytime somnolence, contributing to improved comfort during symptomatic periods.

Amfexa (dexamfetamine) is officially authorized for use in children and adolescents aged 6 to 17 years for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and only when initial treatment with methylphenidate was not clinically adequate. It is not for use in children under 6 years of age or adults.

Use of Amfexa is prohibited (contraindicated) for numerous conditions and patient groups, including:

• Patients with known hypersensitivity to amfetamine or its components.
• Individuals with pre-existing cardiovascular disorders, such as structural cardiac abnormalities, heart failure, severe hypertension, or advanced arteriosclerosis.
• Patients with certain cerebrovascular disorders, including stroke or cerebral aneurysm.
• Those with pre-existing psychiatric conditions like severe depression, psychotic symptoms, or uncontrolled Type I bipolar disorder.
• Concomitant use with, or within 14 days of stopping, a Monoamine Oxidase Inhibitor (MAOI).
• Conditions such as hyperthyroidism, glaucoma, or a history of drug or alcohol abuse.

Amfexa is contraindicated during pregnancy and should not be used while breastfeeding. Patients with kidney or liver impairment should be treated with special consideration due to a lack of complete data on its use in these populations.

Interactions with other medicines and products

Official regulatory documents define specific interaction patterns for Amfexa (dexamfetamine sulfate), categorized by the mechanism of interaction and the substance involved.

Interaction Classifications

Classification	Interacting Substance/Condition
Formally Contraindicated	Monoamine Oxidase Inhibitors (MAOIs), including the antibiotic linezolid. A 14-day washout period is mandatory after stopping an MAOI.
Pharmacokinetic Alteration	Substances that alter gastrointestinal or urinary pH (e.g., ascorbic acid, sodium bicarbonate) can change the drug's absorption and clearance, leading to lower or higher blood levels.
Metabolic Pathway Effect	Co-administration with potent CYP2D6 inhibitors may increase the plasma exposure and concentration of dexamfetamine.

---

Pharmacodynamic Interactions

Several pharmacodynamic interactions are officially documented:

• Serotonergic Agents: Medicines such as SSRIs, SNRIs, and the herbal product St. John's Wort increase the documented risk of serotonin syndrome due to additive effects.
• Adrenergic Blockers: The drug may counteract the effects of blood pressure-lowering medicines, such as antihypertensives.
• Antipsychotics: Certain antipsychotic agents (e.g., chlorpromazine) may inhibit the central stimulant effects of Amfexa.
• Alcohol: Official labeling advises patients to avoid alcohol as it may worsen treatment-related effects.

Core Action: Inducing Monoamine Release and Blocking Reuptake

The physiological effects of Dexamfetamine (Amfexa) are governed by its engagement with the brain’s monoaminergic signaling systems, primarily focusing on dopamine and norepinephrine. The drug functions as a monoamine releasing agent by targeting the Dopamine Transporter (DAT) and Norepinephrine Transporter (NET). Dexamfetamine acts as a substrate, promoting the reversal of these transporters to actively pump dopamine and norepinephrine into the synaptic space. Simultaneously, it inhibits the reuptake mechanism, preventing the rapid clearance of these neurotransmitters. This action, alongside the displacement of monoamines from storage via VMAT2, leads to a robust and sustained increase in synaptic neurotransmitter concentrations.

---

Physiological Consequence: Modulation of Frontal Lobe Signaling

The resulting chemical surge heavily modulates the Frontostriatal Network and the Prefrontal Cortex (PFC), areas crucial for the physiological regulation of executive function and arousal. The modulated signaling in these circuits adjusts the neural signal-to-noise ratio. This specific action enhances the neural mechanism for sustained attentional processing and the physiological filtering of competing stimuli.

---

Mechanistic Constraint: Dependency and Adaptation

The long-term physiological efficacy of this mechanism is inherently linked to the availability of presynaptic neurotransmitter stores and the sensitivity of the post-synaptic receptors. Continuous high-level stimulation can lead to receptor desensitization and adaptation pathways, representing a key biological constraint on the sustained mechanistic output.

How to Use Amfexa: Administration Guidelines

Amfexa is an immediate-release tablet containing dexamfetamine sulfate, and its usage is defined by prescribing information. The medication is designated solely for oral administration.

Dosing and Administration Schedule

Instruction	Guideline
Route of Administration	Oral intake of the tablet form.
Dosing Schedule	Treatment must start at the lowest possible dose (e.g., 5 mg once or twice daily) and be increased gradually in increments of 5 mg at weekly intervals. The total daily dose is typically divided and administered in two or three portions.
Timing & Frequency	The dose may be taken with or without food. To prevent sleep disturbance, the final daily dose should not be taken too late in the afternoon.
Tablet Handling	The scored tablet can be broken along the score line only to aid in swallowing and is not intended to divide the tablet into equal doses. The tablet must be swallowed with liquid.
Missed Dose	If a dose is missed, it should be skipped. The patient should proceed to take the next dose at the regularly scheduled time, and a double dose must not be taken to compensate.

---

Age-Specific Rules and Management

Instructions specify that Amfexa is not recommended for treatment initiation in children under 6 years of age or in older adults, due to the lack of established safety and efficacy data for this product in these populations.

For long-term use (exceeding 12 months), the need for continued therapy must be periodically re-evaluated by the prescriber. This management protocol includes standard procedural steps, such as trial periods off medication at least once yearly, to assess the ongoing necessity of the drug. The use protocol is structured to ensure that administration is guided by initiation and maintenance principles, adhering to documented maximum daily dose limits.

Mechanism of Action

Research has investigated the role of Amfexa (dexamfetamine) in central nervous system function, particularly regarding inflammatory and neurotransmitter pathways. Studies have evaluated whether its use affects specific processes that research suggests may be relevant to the disease.

---

Key Clinical Studies

Studies have investigated Amfexa as a potential therapy for its approved indication, Attention-Deficit/Hyperactivity Disorder (ADHD), typically in children and adolescents aged 6 to 17 years who have had an inadequate response to methylphenidate treatment. These studies focus on patient tolerability and associations between its use and changes in symptoms over time.

1. Randomized Controlled Trials (RCTs)

• Pediatric Studies: Clinical trials have examined the use of dexamfetamine in children and adolescents with ADHD. One non-interventional study involving 140 patients reported that participants experienced a reduction in ADHD symptom severity scores, which was sustained over a 12-month period. Researchers reported mild gastrointestinal discomfort among the most common observations in these trials.
• Long-Term Use: The safety and efficacy of the use of dexamfetamine for extended periods (over 12 months) has not been systematically evaluated in long-term controlled trials. For patients on long-term therapy, continuous monitoring of cardiovascular status, growth, appetite, and psychiatric status is advised based on clinical practice.

2. Safety in Specific Populations

• Cardiovascular Health: Research has investigated the relationship between the use of CNS stimulants, including dexamfetamine, and outcomes in individuals with pre-existing heart issues. Data from large meta-analyses, for instance, have contributed to the overall understanding of risks, especially regarding sudden death, heart attack, and stroke, noting that these events are rare at typical therapeutic doses.

Common questions about Amfexa (FAQ)

Q: What is the active substance in Amfexa and how does it work?

The active substance in Amfexa is dexamfetamine sulfate. According to the official product information, this medicine is classified as a psychostimulant. Official product information indicates this medicine is used to influence the activity of certain chemicals in the brain.

Q: What condition is Amfexa used to treat?

Amfexa is licensed for use as part of a comprehensive treatment program for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years and over and in adults. It is generally reserved for use when the patient's initial response to treatment for ADHD has been unsatisfactory.

Q: What is the typical starting age for children to use Amfexa?

Regulatory documents state that Amfexa is licensed for use in children from 6 years of age and over. Official information indicates that this medicine is intended to be used as part of a comprehensive treatment plan supervised by a specialist in behavioral disorders or psychiatry.

Q: Can Amfexa be used long-term?

Studies and official information indicate that long-term use of Amfexa requires continuous specialist monitoring. Regulatory sources recommend treatment be interrupted periodically to allow the supervising specialist to assess if the medicine is still needed and to monitor the patient's condition without it. The decision for ongoing use is made by the prescribing specialist.

Q: What is the goal of a "drug holiday" or treatment interruption?

A "drug holiday" or treatment interruption is a scheduled period where the patient temporarily stops taking the medicine. The primary aim is to allow the specialist to check whether the ongoing use of the medicine is still providing benefit and to assess the patient's behavior without the drug. This assessment informs the specialist's decision on continuing treatment.

Q: Is there a risk of developing dependence on Amfexa?

According to the official product information, there is a risk of developing drug tolerance and psychological dependence when using Amfexa. Due to the potential for tolerance and dependence, continuous medical supervision is necessary throughout the course of treatment, as noted in regulatory documents.

Q: What are some very common issues that patients may experience while taking Amfexa?

Official sources list loss of appetite and insomnia (difficulty sleeping) as very common issues that may be experienced by patients. These are defined as affecting more than 1 in 10 people. Patients are advised to always report any new issues or changes to their treating specialist.

Q: Can Amfexa affect a person's blood pressure or heart rate?

Yes, regulatory documents indicate that Amfexa can cause a minor increase in blood pressure and heart rate. For this reason, official guidance recommends that heart rate and blood pressure should be monitored at appropriate intervals during treatment under the specialist's care.

How to Store and Dispose of Amfexa

Official regulatory documents define strict requirements for the storage and disposal of Amfexa (dexamfetamine sulfate) to maintain its quality and prevent misuse.

Storage Requirements

• Temperature: Amfexa must be stored at a temperature not exceeding 25°C (controlled room temperature) to ensure its chemical stability and maintain its 3-year shelf-life.
• Packaging: Keep the tablets in the original container/blister pack for protection from light and moisture.
• Security: Due to its classification as a controlled substance, the medication must be stored out of the sight and reach of children. Regulatory guidance strongly advises keeping it in a safe, locked place to prevent theft and misuse.

Disposal Instructions

Do not dispose of Amfexa in household trash or wastewater. Any unused or expired medicine must be disposed of according to local regulations. Patients should utilize community drug take-back programs or authorized collection points, as this is the preferred method for the regulated disposal of controlled substances.